Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 receptor tri-agonist for obesity and type 2 diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 receptor tri-agonist for obesity and type 2 diabetes.
- Published In:
- International journal of biological macromolecules, 328(Pt 1), 147553 (2025)
- Authors:
- Liu, Xiyu, Gong, Binbin, Wang, Ting, Hu, Guoqiang, Han, Jing, Sun, Lidan
- Database ID:
- RPEP-12251
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12251APA
Liu, Xiyu; Gong, Binbin; Wang, Ting; Hu, Guoqiang; Han, Jing; Sun, Lidan. (2025). Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 receptor tri-agonist for obesity and type 2 diabetes.. International journal of biological macromolecules, 328(Pt 1), 147553. https://doi.org/10.1016/j.ijbiomac.2025.147553
MLA
Liu, Xiyu, et al. "Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 receptor tri-agonist for obesity and type 2 diabetes.." International journal of biological macromolecules, 2025. https://doi.org/10.1016/j.ijbiomac.2025.147553
RethinkPeptides
RethinkPeptides Research Database. "Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 r..." RPEP-12251. Retrieved from https://rethinkpeptides.com/research/liu-2025-development-of-a-potent
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.